Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 547261 - 547280 out of 553680 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| USA | (M05BX04) denosumab (adm: P) | OSENVELT 120 MG/1.7 ML INJ | 1.7ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Giant Cell Tumor of Bone;Neoplasms, Bone Tissue | CelltrionUSA,Inc. |
| USA | (M05BX04) denosumab (adm: P) | XGEVA 120MG/1.7ML INJ | 1.7ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Giant Cell Tumor of Bone;Neoplasms, Bone Tissue | AmgenUSA,Inc. |
| USA | (M05BX04) denosumab (adm: P) | XGEVA 120MG/1.7ML INJ | 1.7ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Giant Cell Tumor of Bone;Neoplasms, Bone Tissue | AmgenUSA,Inc. |
| USA | (M05BX04) denosumab (adm: P) | STOBOCLO 60MG/ML INJ,SYRINGE,1ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Osteoporosis, Postmenopausal;Osteoporosis;Bone Resorption | CelltrionUSA,Inc. |
| USA | (M05BX04) denosumab (adm: P) | PROLIA 60MG INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Bone Resorption;Osteoporosis, Postmenopausal;Osteoporosis | AmgenUSA,Inc. |
| USA | (M05BX04) denosumab (adm: P) | PROLIA 60MG INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Bone Resorption;Osteoporosis, Postmenopausal;Osteoporosis | AmgenUSA,Inc. |
| USA | (M05BX04) denosumab (adm: P) | PROLIA 60MG INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Bone Resorption;Osteoporosis, Postmenopausal;Osteoporosis | AmgenUSA,Inc. |
| USA | (M05BX04) denosumab (adm: P) | PROLIA 60MG INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Bone Resorption;Osteoporosis, Postmenopausal;Osteoporosis | AmgenUSA,Inc. |
| USA | (M05BX05) burosumab (adm: P) | CRYSVITA 10MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
| USA | (M05BX05) burosumab (adm: P) | CRYSVITA 10MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
| USA | (M05BX05) burosumab (adm: P) | CRYSVITA 20MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
| USA | (M05BX05) burosumab (adm: P) | CRYSVITA 20MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
| USA | (M05BX05) burosumab (adm: P) | CRYSVITA 30MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
| USA | (M05BX05) burosumab (adm: P) | CRYSVITA 30MG/ML | 1ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia | KyowaKirin,Inc. |
| USA | (M05BX06) romosozumab (adm: P) | EVENITY 105MG/1.17ML INJ,PFS | 2X1.17ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Osteoporosis | AmgenUSA,Inc. |
| USA | (M05BX06) romosozumab (adm: P) | EVENITY 105MG/1.17ML INJ,PFS | 2X1.17ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Osteoporosis | AmgenUSA,Inc. |
| USA | (M05BX06) romosozumab (adm: P) | EVENITY 105MG/1.17ML INJ,SOLN SYR | 2X1.17ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Osteoporosis | AmgenUSA,Inc. |
| USA | (M05BX06) romosozumab (adm: P) | EVENITY 105MG/1.17ML INJ,SOLN SYR | 2X1.17ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Osteoporosis | AmgenUSA,Inc. |
| USA | (M05BX07) vosoritide | VOXZOGO 0.4MG/VIL INJ | 10 | Ex-factory price without vat |
$0-0 |
$0-0 |
Achondroplasia | BioMarinPharmaceutical,Inc. |
| USA | (M05BX07) vosoritide | VOXZOGO 0.4MG/VIL INJ | 10 | Ex-factory price without vat |
$0-0 |
$0-0 |
Achondroplasia | BioMarinPharmaceutical,Inc. |
Pages
